GTC
Ghost Tree Capital Portfolio holdings
AUM
$276M
This Quarter Return
+56.3%
1 Year Return
+49.13%
3 Year Return
+198.45%
5 Year Return
+1,783.74%
10 Year Return
+9,775.89%
AUM
$303M
AUM Growth
+$303M
(+34%)
Cap. Flow
-$50.7M
Cap. Flow
% of AUM
-16.7%
Top 10 Holdings %
Top 10 Hldgs %
52.23%
Holding
56
New
9
Increased
10
Reduced
15
Closed
12
Top Buys
| 1 |
Acadia Pharmaceuticals
ACAD
|
$8M |
| 2 |
TG Therapeutics
TGTX
|
$7.79M |
| 3 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$6.47M |
| 4 |
Iovance Biotherapeutics
IOVA
|
$6.31M |
| 5 |
Agios Pharmaceuticals
AGIO
|
$6.15M |
Top Sells
| 1 |
Mersana Therapeutics
MRSN
|
$32.2M |
| 2 |
IMMU
Immunomedics Inc
IMMU
|
$16.8M |
| 3 |
Ascendis Pharma
ASND
|
$12.6M |
| 4 |
Axsome Therapeutics
AXSM
|
$9.46M |
| 5 |
Adverum Biotechnologies
ADVM
|
$8.47M |
Sector Composition
| 1 | Healthcare | 88.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
KalVista Pharmaceuticals
KALV
$678M
| $4.24M | 1.12% | 350,000 | – | – |
|
27
Aldeyra Therapeutics
ALDX
$351M
| $4.17M | 1.1% | +1,000,000 | New | +$4.17M |
|
28
Xenon Pharmaceuticals
XENE
$2.98B
| $4.08M | 1.08% | 325,000 | – | – |
|
29
Arvinas
ARVN
$568M
| $4.03M | 1.06% | 120,000 +40,000 | +50% | +$1.34M |
|
30
Q32 Bio
QTTB
$20.9M
| $3.57M | 0.94% | 235,000 +35,000 | +18% | +$532K |
|
31
Cartesian Therapeutics
RNAC
$261M
| $2.84M | 0.75% | 1,000,000 -725,000 | -42% | -$2.06M |
|
32
Syndax Pharmaceuticals
SNDX
$1.41B
| $2.74M | 0.72% | 185,000 -65,000 | -26% | -$963K |
|
33
Gilead Sciences
GILD
$140B
| $1.92M | 0.51% | +25,000 | New | +$1.92M |
|
34
PolyPid
PYPD
$53.3M
| $1.8M | 0.48% | +100,000 | New | +$1.8M |
|
35
Altimmune
ALT
$338M
| $1.61M | 0.42% | +150,000 | New | +$1.61M |
|
36
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $1.27M | 0.34% | 50,000 -62,695 | -56% | -$1.6M |
|
|
VRAY
37
DELISTED
ViewRay, Inc.
VRAY
| $672K | 0.18% | 300,000 -482,928 | -62% | -$1.08M |
|
38
Moderna
MRNA
$9.37B
| $642K | 0.17% | +10,000 | New | +$642K |
|
39
Invesco CurrencyShares Euro Currency Trust
FXE
$529M
| $212K | 0.06% | 2,000 -18,830 | -90% | -$2M |
|
|
AMRN
40
Amarin Corp
AMRN
$311M
| – | – | 0 | – | – |
|
41
Biogen
BIIB
$19.4B
| – | – | -3,250 | Closed | -$1.03M |
|
42
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| – | – | -150,000 | Closed | -$2.43M |
|
43
Cue Biopharma
CUE
$60M
| – | – | -125,000 | Closed | -$1.77M |
|
44
Milestone Pharmaceuticals
MIST
$156M
| – | – | -208,733 | Closed | -$384K |
|
45
Protagonist Therapeutics
PTGX
$3.67B
| – | – | -227,827 | Closed | -$1.61M |
|
46
Invesco QQQ Trust
QQQ
$364B
| – | – | 0 | – | – |
|
|
SAGE
47
DELISTED
Sage Therapeutics
SAGE
| – | – | -65,000 | Closed | -$1.87M |
|
48
SPDR S&P 500 ETF Trust
SPY
$658B
| – | – | 0 | – | – |
|
49
Verastem
VSTM
$569M
| – | – | -1,500,000 | Closed | -$3.96M |
|
50
SPDR S&P Biotech ETF
XBI
$5.07B
| – | – | 0 | – | – |
|